Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 13/20 | 0.39 |
| ▸ | FEN1 | P39748 | 13/20 | 0.39 |
| ▸ | NAAA | Q02083 | 2/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14815787 | 0.93 | ALOX5AP (0.41) | ALOX5APFEN1SMN1; SMN2MAPK1 | |
| SCHEMBL14815679 | 0.92 | CYP19A1 (0.37) | ALOX5APFEN1SMN1; SMN2SCN3APKM | |
| SCHEMBL15462515 | 0.91 | CHRM1 (0.41) | ALOX5APFEN1NAAACHRM1SCN3A | |
| SCHEMBL14815880 | 0.91 | CHRM1 (0.41) | ALOX5APFEN1NAAACHRM1SCN3A | |
| SCHEMBL14815380 | 0.90 | PKM (0.41) | ALOX5APFEN1NAAAPKM | |
| SCHEMBL15462462 | 0.90 | PKM (0.41) | ALOX5APFEN1NAAAPKM | |
| SCHEMBL15462474 | 0.88 | ALOX5AP (0.39) | ALOX5APFEN1USP2PKMMAPK1 | |
| SCHEMBL14815548 | 0.88 | ALOX5AP (0.39) | ALOX5APFEN1USP2PKMMAPK1 | |
| SCHEMBL14815542 | 0.86 | CNR1 (0.43) | ALOX5APFEN1 | |
| SCHEMBL14815945 | 0.86 | PKM (0.40) | ALOX5APFEN1SMN1; SMN2SCN3APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8648074-B2 | Substituted octahydropyrrolo[1,2-a]pyrazine sulfonamides as calcium channel blockers | ABBVIE INC. (US) | 2014-02-11 | — | — | US | claimed |
| US-20130085141-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINE SULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | ABBVIE INC. (US) | 2013-04-04 | — | — | US | claimed |
| US-8648074-B2 | Substituted octahydropyrrolo[1,2-a]pyrazine sulfonamides as calcium channel blockers | ABBVIE INC. (US) | 2014-02-11 | — | — | US | disclosed |
| US-20130085141-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINE SULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | ABBVIE INC. (US) | 2013-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085141-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINE SULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | CACNA1C, CACNA1D, CACNA1A | ALOX5AP 649/4885FEN1 4851/4885NAAA 2548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.